Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Acquisitions & Divestments (2016 - 2017)

Adma Biologics (ADMA) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $245000.0 as the latest value for Q2 2017.

  • For the quarter ending Q2 2017, Change in Acquisitions & Divestments rose 106.67% year-over-year to $245000.0, compared with a TTM value of $245000.0 through Mar 2018, down 98.65%, and an annual FY2017 reading of $5.4 million, down 67.64% over the prior year.
  • Change in Acquisitions & Divestments was $245000.0 for Q2 2017 at Adma Biologics, down from $5.1 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $16.7 million in Q4 2016 and bottomed at -$3.7 million in Q2 2016.